List of Excipients in Branded Drug PIOGLITAZONE AND GLIMEPIRIDE

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Prasco Laboratories	PIOGLITAZONE AND GLIMEPIRIDE	pioglitazone and glimepiride	66993-821	CELLULOSE, MICROCRYSTALLINE
Prasco Laboratories	PIOGLITAZONE AND GLIMEPIRIDE	pioglitazone and glimepiride	66993-821	CROSCARMELLOSE SODIUM
Prasco Laboratories	PIOGLITAZONE AND GLIMEPIRIDE	pioglitazone and glimepiride	66993-821	HYDROXYPROPYL CELLULOSE

Pioglitazone and Glimepiride Excipient Strategy and Commercial Opportunities

Last updated: August 22, 2026

Pioglitazone/glimepiride is an established fixed-dose combination for type 2 diabetes, marketed in the United States as Duetact and available through generic competition. The active ingredients are mature, low-cost compounds with limited remaining composition-of-matter protection. Commercial value therefore depends on manufacturing efficiency, bioequivalence execution, excipient differentiation, supply reliability, and targeted lifecycle products rather than broad molecule-level exclusivity.

The strongest opportunities are low-cost generic tablets, lactose-free or low-allergen versions, improved direct-compression platforms, pediatric or geriatric swallowability solutions, and carefully designed 505(b)(2) products. Excipient changes that materially alter dissolution, absorption, or dose uniformity create regulatory and patent risk.

What is the pioglitazone and glimepiride fixed-dose combination?

Pioglitazone is a thiazolidinedione insulin-sensitizing agent. Glimepiride is a sulfonylurea that stimulates pancreatic insulin release. The combination is used with diet and exercise to improve glycemic control in adults with type 2 diabetes when dual therapy is appropriate.[1]

Duetact contains pioglitazone hydrochloride and glimepiride in a once-daily tablet. U.S. labeling identifies four principal strengths:

Pioglitazone component	Glimepiride component
30 mg	2 mg
30 mg	4 mg
45 mg	2 mg
45 mg	4 mg

The labeled product is taken with the first main meal of the day. The two drugs have different safety limitations. Pioglitazone carries a boxed warning concerning congestive heart failure, while glimepiride can cause severe hypoglycemia. Excipients can improve manufacturability and patient acceptability but do not remove those pharmacologic risks.[1]

What excipients are used in pioglitazone and glimepiride tablets?

The reference product uses conventional immediate-release tablet excipients. Public labeling identifies lactose monohydrate, hydroxypropyl cellulose, carboxymethylcellulose calcium, magnesium stearate, and polysorbate 80 among the inactive ingredients.[1,2]

The formulation architecture is commercially significant:

Excipient or excipient class	Primary function	Commercial relevance
Lactose monohydrate	Diluent and tablet bulk	Low cost, established supply, but unsuitable for lactose-free positioning
Hydroxypropyl cellulose	Binder and processing aid	Supports granulation and mechanical strength
Carboxymethylcellulose calcium	Disintegrant	Helps achieve immediate release
Magnesium stearate	Lubricant	Reduces sticking and ejection force; excessive use can slow dissolution
Polysorbate 80	Wetting or formulation aid	May assist drug dispersion and process consistency

The precise qualitative and quantitative formula of the reference product is not necessarily disclosed in the public label. A generic manufacturer must develop its own formulation and demonstrate pharmaceutical equivalence and bioequivalence under the applicable abbreviated new drug application pathway.[3]

Why are excipient choices technically difficult?

Glimepiride is present at a relatively low dose compared with the total tablet mass. This creates content-uniformity and segregation risks during blending and compression. Pioglitazone hydrochloride contributes a larger mass but still requires controlled particle-size distribution and mixing.

The main development variables are:

• Blend uniformity for the low-dose glimepiride fraction.
• Drug distribution after granulation or direct compression.
• Lubrication time and magnesium stearate concentration.
• Tablet hardness versus disintegration time.
• Dissolution across relevant pH conditions.
• Moisture sensitivity and physical stability.
• Compression behavior across all strengths.
• Scale-up reproducibility.

A formulation that performs well in the 45 mg/4 mg strength may not transfer directly to the 30 mg/2 mg strength. The lower glimepiride dose increases the risk of segregation and assay variability. A common platform may be commercially desirable, but each strength requires independent validation.

What excipient strategy is strongest for a generic pioglitazone/glimepiride product?

The strongest base strategy is a conventional immediate-release tablet using a robust, low-cost manufacturing process. Direct compression is attractive when both active ingredients and the selected excipients provide adequate flow and content uniformity. Wet granulation may provide better control of segregation and compactability but increases process steps, water exposure, drying requirements, and cost.

Strategy 1: Conventional lactose-containing generic

This is the lowest-risk development path when the product can meet dissolution, assay, content uniformity, stability, and bioequivalence requirements.

Commercial advantages include:

• Broad excipient availability.
• Established regulatory precedent.
• Low manufacturing cost.
• Simple supply-chain qualification.
• Straightforward tablet compression and coating.

The primary disadvantage is limited differentiation. Multiple suppliers can compete on price, making manufacturing yield and procurement economics more important than formulation novelty.

Strategy 2: Lactose-free formulation

A lactose-free tablet can replace lactose with microcrystalline cellulose, mannitol, dibasic calcium phosphate, starch-based excipients, or a co-processed filler system. The commercial target includes patients with lactose intolerance, institutional buyers with excipient restrictions, and markets where lactose-free labeling has value.

The main technical risks are altered:

• Tablet density.
• Disintegration time.
• Moisture uptake.
• Compression force.
• Dissolution profile.
• Stability of the low-dose glimepiride component.

Mannitol may improve mouthfeel but can increase cost. Dibasic calcium phosphate can improve compactability but may affect dissolution and is less suitable for certain formulation designs. Microcrystalline cellulose is widely used but can produce different tablet tensile strength and lubricant sensitivity than lactose.

Strategy 3: Low-weight, high-strength tablet platform

A co-processed excipient system can reduce tablet weight and improve compression at high production speeds. This may support smaller tablets, lower packaging volume, and fewer manufacturing defects.

The opportunity is strongest in the 30 mg/2 mg and 30 mg/4 mg strengths, where tablet size can be reduced without changing the active doses. The regulatory burden remains manageable if the product remains an immediate-release oral tablet and the dissolution profile remains comparable.

Strategy 4: Geriatric swallowability formulation

Patients with type 2 diabetes are often older and may take several medicines. Smaller tablets, film-coating optimization, reduced tablet friability, and improved surface smoothness can create practical value without changing the release mechanism.

An orally disintegrating tablet, orally dispersible tablet, or mini-tablet product could offer greater differentiation. These products introduce higher development risk because glimepiride taste, dose uniformity, in-mouth disintegration, excipient tolerability, and systemic exposure must be controlled. A nonconventional dosage form would generally require a more extensive regulatory strategy than a standard ANDA formulation.

What formulation patents could protect pioglitazone and glimepiride products?

New excipient combinations can be patentable only when they satisfy novelty, non-obviousness, written-description, enablement, and utility requirements. A simple substitution of lactose with microcrystalline cellulose is unlikely to provide durable protection without an unexpected technical result.

Potential claim themes include:

• A specific excipient ratio producing a defined dissolution profile.
• A low-dose glimepiride blending process that achieves a defined content-uniformity range.
• A moisture-controlled formulation with improved stability.
• A co-processed excipient system that reduces segregation.
• A tablet architecture that improves mechanical strength at lower weight.
• A taste-masked or orally disintegrating formulation.
• A specific coating system that improves swallowability or chemical stability.
• A manufacturing process that reduces degradation or batch variability.

The strongest formulation patent strategy would link composition to measurable performance. Claims directed only to broad classes of common excipients face substantial obviousness risk.

How strong is the formulation patent estate?

The formulation patent estate is likely to be materially stronger than the remaining active-ingredient estate only for genuinely differentiated dosage forms or manufacturing processes. Conventional immediate-release tablets have limited defensive value because many excipient combinations are predictable and widely used.

Patent strength should be assessed across five factors:

1. Claim breadth and dependence on narrow excipient ratios.
2. Availability of non-infringing substitute excipients.
3. Whether the claimed result is unexpected and reproducible.
4. Ability to detect infringement from public product information.
5. Regulatory relevance of the claimed formulation.

A process patent may be commercially weak if competitors can reach the same product through an alternative process. A composition patent may be stronger if the protected excipient architecture is necessary to achieve the claimed dissolution or stability result.

What is the FDA regulatory status of pioglitazone and glimepiride?

The fixed-dose combination is an approved small-molecule oral product, not a biologic. Biosimilar risk does not apply. Competitive entry occurs through generic-drug pathways, principally an ANDA for a pharmaceutically equivalent and bioequivalent product.[3]

The regulatory profile is summarized below:

Issue	Assessment
Product type	Immediate-release oral fixed-dose combination
Active ingredients	Pioglitazone hydrochloride and glimepiride
Reference product	Duetact
FDA pathway for standard generic	ANDA
Likely pathway for materially different dosage form	505(b)(2) NDA
Biosimilar pathway	Not applicable
Therapeutic category	Type 2 diabetes
Key clinical risks	Heart failure and edema from pioglitazone; hypoglycemia from glimepiride
Main formulation controls	Assay, content uniformity, dissolution, impurities, stability, bioequivalence

FDA approval of a generic product does not require the generic to duplicate every inactive ingredient in the reference product. The proposed formulation must comply with applicable inactive-ingredient requirements and demonstrate that formulation differences do not create safety or efficacy problems.[3,4]

What is the Orange Book status and patent risk?

The Orange Book is the principal U.S. source for listed patents and regulatory exclusivity associated with approved drug products.[5] Pioglitazone and glimepiride are mature small molecules. Their original active-ingredient patent protections have expired or are no longer the principal barrier to ordinary generic competition in the United States.

For a current product-specific diligence review, the relevant records are:

• The Duetact reference listing.
• Any listed patents associated with the NDA.
• Any pediatric or other statutory exclusivity.
• Approved generic products and their therapeutic equivalence ratings.
• Current patent certifications and litigation entries.

Paragraph IV risk is generally limited for a mature combination unless a listed formulation, method-of-use, or manufacturing patent remains enforceable. A generic applicant may file a Paragraph IV certification against an unexpired listed patent and trigger potential Hatch-Waxman litigation. If no relevant unexpired patents remain, the principal competitive risks shift to regulatory review, manufacturing scale-up, supply continuity, and pricing.

When did pioglitazone and glimepiride lose exclusivity?

Glimepiride and pioglitazone are long-established drugs. Their core molecule-level exclusivity has ended, and the combination is no longer protected by meaningful new-drug exclusivity in the ordinary commercial sense.

The commercial timeline is:

Period	Commercial implication
Original molecule development	Protection centered on active compounds and early formulations
Combination approval	Duetact established the fixed-dose product
Post-approval lifecycle	Potential protection moved toward formulation, use, and process claims
Current market	Generic competition and cost leadership dominate
Future opportunity	Differentiated dosage forms, excipient systems, and regional supply models

Exact patent expiration analysis must be performed against the current Orange Book record and relevant national registers because listed patents, terminal disclaimers, pediatric extensions, and litigation outcomes can change the operative date.[5]

Which companies are challenging or competing with the reference product?

Competition comes from three groups:

1. Generic manufacturers with ANDA-approved pioglitazone/glimepiride products.
2. Manufacturers selling the two active ingredients separately.
3. Diabetes companies offering competing combination therapies, including metformin-based regimens, DPP-4 inhibitor combinations, SGLT2 inhibitor combinations, and GLP-1 products.

The fixed-dose combination competes on acquisition cost and pill burden. It competes less effectively on newer guideline positioning because pioglitazone can cause weight gain, edema, and fracture risk, while glimepiride carries hypoglycemia risk. Newer agents may command a premium where cardiovascular, renal, weight, or hypoglycemia outcomes drive treatment selection.[6]

What commercial opportunities exist for excipient suppliers and drug manufacturers?

Excipient suppliers

Excipient suppliers can target:

• Direct-compression systems for low-dose drug uniformity.
• Lactose-free filler-binder platforms.
• Low-moisture systems for improved stability.
• Co-processed excipients that reduce segregation.
• Film-coating systems optimized for small tablets.
• Low-cost, globally qualified alternatives to single-source materials.

The value proposition must be supported by production data, not only by a list of excipient functions. Manufacturers will prioritize yield, tablet-speed performance, dissolution robustness, and regulatory documentation.

Generic drug manufacturers

The most practical opportunity is a multi-strength, common-platform product with:

• Low tablet weight.
• High content-uniformity capability.
• Stable dissolution after scale-up.
• Multiple qualified excipient suppliers.
• Efficient packaging and serialization.
• Competitive cost per tablet.

A lactose-free version can support differentiated tendering and pharmacy positioning. A smaller, easier-to-swallow tablet can support institutional purchasing but may provide limited pricing power unless protected by a meaningful patent or difficult-to-replicate process.

Licensing opportunities

Licensing value is most credible for:

• A protected orally disintegrating or dispersible formulation.
• A validated low-dose blending process.
• A platform that improves stability in hot and humid markets.
• A regional manufacturing process with qualified local excipient supply.
• A differentiated combination that adds another antidiabetic active under a defensible regulatory strategy.

A conventional generic formula has limited licensing value because the market has many substitutable formulation routes.

What generic launch risks exist?

The main launch risks are operational rather than molecule-level patent risks:

• Failure to demonstrate bioequivalence.
• Dissolution mismatch between strengths.
• Glimepiride content-uniformity failures.
• Scale-up segregation.
• Magnesium stearate over-lubrication.
• Excipient supply interruptions.
• Labeling or inactive-ingredient compliance issues.
• Price erosion after multiple generic launches.
• Limited demand because physicians favor newer diabetes therapies.
• Product liability exposure linked to hypoglycemia or heart-failure warnings.

A formulation that reduces manufacturing cost but creates dissolution variability is unlikely to produce sustainable commercial value. The preferred strategy is a conservative immediate-release platform with targeted excipient differentiation and strong process controls.

Key Takeaways

• Pioglitazone/glimepiride is a mature fixed-dose combination with limited remaining molecule-level exclusivity.
• Duetact uses conventional tablet excipients, including lactose monohydrate, hydroxypropyl cellulose, carboxymethylcellulose calcium, magnesium stearate, and polysorbate 80.
• The best generic strategy is a low-cost immediate-release tablet with strong glimepiride content uniformity and robust dissolution.
• Lactose-free, smaller, low-moisture, and geriatric-friendly formulations offer the clearest commercial differentiation.
• Conventional excipient substitutions have weak patent potential unless tied to unexpected performance or a difficult manufacturing process.
• Biosimilar risk is irrelevant because both actives are small molecules.
• Paragraph IV exposure depends on the current Orange Book listing and any surviving formulation, method-of-use, or process patents.
• Generic launch economics will be driven by manufacturing yield, supply reliability, procurement cost, and the competitive position of older diabetes therapies.

FAQs

Can lactose be removed from a pioglitazone/glimepiride tablet?

Yes. Lactose can be replaced with excipients such as microcrystalline cellulose, mannitol, starch-based materials, or dibasic calcium phosphate. The replacement must be evaluated for content uniformity, dissolution, stability, compression, and bioequivalence.

Is pioglitazone/glimepiride eligible for a biosimilar application?

No. Pioglitazone and glimepiride are chemically synthesized small molecules. A conventional generic drug application, not a biosimilar application, is the relevant U.S. pathway.

Can an excipient supplier patent a lactose-free formulation?

Possibly, but a broad lactose-free claim is unlikely to be strong by itself. Patent value increases when the formulation uses a defined excipient architecture that produces unexpected dissolution, stability, uniformity, or manufacturing results.

Is an orally disintegrating pioglitazone/glimepiride product commercially attractive?

It may address swallowability and adherence, but development risk is higher than for a standard tablet. Taste masking, dose uniformity, in-mouth performance, stability, and regulatory requirements can offset the commercial benefit.

What is the most valuable manufacturing improvement for this combination?

Improved glimepiride content uniformity across commercial-scale batches is likely to have the greatest practical value. It can reduce rejects, improve regulatory confidence, and support a common platform across multiple strength combinations.

References

1. U.S. Food and Drug Administration. (n.d.). Duetact: Pioglitazone hydrochloride and glimepiride tablets, prescribing information. Drugs@FDA.

2. National Library of Medicine. (n.d.). Duetact- pioglitazone hydrochloride and glimepiride tablet. DailyMed.

3. U.S. Food and Drug Administration. (2014). Guidance for industry: ANDAs for certain highly purified synthetic peptide drug products that refer to listed drugs of recombinant origin. FDA.

4. U.S. Food and Drug Administration. (2016). Inactive ingredient database. FDA.

5. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations. FDA Orange Book.

6. American Diabetes Association Professional Practice Committee. (2024). 9. Pharmacologic approaches to glycemic treatment: Standards of care in diabetes-2024. Diabetes Care, 47(Supplement 1).